Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

Vanucizumab (anti-ANG2&VEGFA) - Primary antibody, specific to VPS51 & VEGFA, Human IgG1, INHIBITOR of Vascular endothelial growth factor A inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefitsView More
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
Ab175696
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175696-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab175696-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$309.90
Ab175696-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$779.90
Ab175696-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,249.90

Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameVanucizumab (anti-ANG2&VEGFA) - Primary antibody, specific to VPS51 & VEGFA, Human IgG1
SynonymsANG2 antibody | ANG3 antibody | Another new gene 2 protein antibody | C11orf3 antibody | chromosome 11 open reading frame 2 antibody | Fat free homolog antibody | ffr antibody | FFR_HUMAN antibody | FFR|FLJ13879 antibody | FLJ36472 antibody | Protein fat-
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥90%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityVPS51 & VEGFA
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Vascular endothelial growth factor A inhibitor
Product Description

Vanucizumab (anti-ANG2 & VEGFA) is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab (anti-ANG2 & VEGFA) has antiangiogenic and anticancer effects.
 Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE146.89 kDa
Purification MethodProtein A purified
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1448221-05-3

Images

Vanucizumab (anti-ANG2&VEGFA) (Ab175696) - ELISA
Immobilized Recombinant Human VEGFA-His protein at 2.0 μg/mL can bind Vanucizumab (anti-ANG2&VEGFA) (Ab175696) with the EC₅₀ of 3.67 ng/mL.

Vanucizumab (anti-ANG2&VEGFA) (Ab175696) - SEC
The purity of Vanucizumab (anti-ANG2&VEGFA) (Ab175696) is more than 95% verified by HPLC.

Certificates

C of A & Other Certificates

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0708982Certificate of AnalysisJul 31, 2024 Ab175696
ZJ24F0708981Certificate of AnalysisJul 31, 2024 Ab175696
ZJ24F0708980Certificate of AnalysisJul 31, 2024 Ab175696

Related Documents

References

1. Spiess C, Zhai Q, Carter PJ.  (2015)  Alternative molecular formats and therapeutic applications for bispecific antibodies..  Mol Immunol,  67  (2 Pt A): (95-106).  [PMID:25637431] [10.1021/op500134e]

Solution Calculators